Jump to content

Feprosidnine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:13, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Feprosidnine
Clinical data
ATC code
  • none
Identifiers
  • 5-Imino-3-(1-phenylpropan-2-yl)-5H-1,2,3-oxadiazol-3-ium-2-ide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H13N3O
Molar mass203.245 g·mol−1
3D model (JSmol)
  • n1oc([NH-])c[n+]1C(Cc2ccccc2)C
  • InChI=1S/C11H13N3O/c1-9(14-8-11(12)15-13-14)7-10-5-3-2-4-6-10/h2-6,8-9,12H,7H2,1H3 checkY
  • Key:HFLCEELTJROKMJ-UHFFFAOYSA-N checkY
  (verify)

Feprosidnine (Sydnophen) is a stimulant drug which was developed in the USSR in the 1970s.[1][2] It is structurally related to another Russian drug mesocarb but unlike mesocarb, was withdrawn earlier from production. In comparison with mesocarb it has own antidepressant activity, which makes it useful in treating depressions. Indications of feprosidnine included apathic, asthenic depressions, fatique, apathic syndrome, narcolepsy and other similar conditions. Therapeutic range of doses: 10-50mg a day. Sydnophen has multiple mechanisms of action, the relative importance of which has not been clearly established. Effects on the body include reversible monoamine oxidase inhibition, cholinergic,[3] adrenergic,[4] opioid[5] and nitric oxide donating[6] actions, all of which may contribute to its pharmacological effects to some extent.

Chemistry

Feprosidnine is a mesoionic sydnone imine.

References

  1. ^ Veksler IG, Riabukha VN, Balitskiĭ KP, Al'tshuler RA, Mashkovskiĭ MD. Immunostimulating and antitumor action of psychotropic preparations of the sydnonimine series. (Russian) Farmakologiia i Toksikologiia. 1980 May-Jun;43(3):349-52.
  2. ^ Koniaeva EI, Beketov AI. Effect of caffeine and sidnofen on the blood supply of the brain, kidneys and hindlimbs during antiorthostatism. (Russian) Farmakologiia i Toksikologiia 1987 May-Jun;50(3):39-42.
  3. ^ Samonina GE, Mandriko EV. Peripheral cholinolytic action--one of the effects of sidnofen. (Russian) Biulleten Eksperimental'noi Biologii i Meditsiny. 1989 Apr;107(4):449-51.
  4. ^ Babskaia NE. Sidnofen-dependent pre- and postsynaptic activation of peripheral adrenergic transmission. (Russian) Eksperimental'naia i Klinicheskaia Farmakologiia. 1992 Sep-Oct;55(5):21-5.
  5. ^ D'iakonova TL, Samonina GE. The naloxone-dependent effects of the psychostimulant sidnofen: a study on identified neurons of the snail. (Russian) Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova. 1994 Jul-Oct;44(4-5):786-95.
  6. ^ Arzamastsev AP, Severina IS, Grigor'ev NB, Granik VG. Exogenous donors of nitric oxide and inhibitors of NO-synthase (chemical aspects). (Russian). Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2003;(12):88-95.